RADX se eleva en 155% con datos de ensayo reveladores: ¿Es este el comienzo de un gran salto de las biotecnologías?

Summary
• Radiopharm Theranostics (RADX) surges 155.87% intraday, trading at $10.90 after a 92% concordance rate in Phase 2b brain metastases trial.
• FDA Fast Track designation for RAD 101 accelerates regulatory pathway, with $500M U.S. market potential highlighted.
• Intraday range of $8.91–$16.25 reflects volatile investor sentiment amid 52-week high of $16.25.

RADX’s meteoric rise on December 15, 2025, underscores a pivotal moment for the biotech sector. The stock’s 155.87% surge, driven by interim Phase 2b trial results showing 92% MRI concordance for RAD 101, has ignited speculative fervor. With the 52-week high breached and a webinar scheduled to detail trial progress, investors are weighing the implications of a potential $500M market capture. The stock’s volatility—swinging from $8.91 to $16.25—reflects both optimism and caution in a high-stakes biotech play.

RAD 101 Trial Success Ignites Biotech Hype
Radiopharm’s 155.87% intraday surge stems from interim Phase 2b trial data showing 92% concordance between RAD 101 PET imaging and MRI in detecting brain metastases. This result, coupled with FDA Fast Track designation, validates the drug’s potential to become a top-three imaging agent in a $500M+ U.S. market. The company’s 50% enrollment in the trial and plans for a pivotal study by late 2026 further stoke investor enthusiasm. With 300,000 annual U.S. brain metastasis cases and limitations in current MRI diagnostics, RAD 101’s tumor-specific FASN targeting positions it as a disruptive force. The webinar on December 15–16 will likely amplify momentum as management outlines next steps.

Biotech Sector Volatility Amid RADX’s Outperformance
The biotech sector remains mixed, with Illumina (ILMN) down 0.11% despite RADX’s surge. While RADX’s 155.87% gain dwarfs sector peers, broader market dynamics—such as regulatory risks and clinical trial uncertainty—persist. The sector’s focus on precision oncology aligns with RADX’s FASN-targeted approach, but its standalone performance highlights the stock’s speculative nature. Investors are cautiously optimistic, balancing RADX’s breakthrough potential against the sector’s inherent volatility.

Navigating RADX’s Volatility: ETFs and Technical Plays
• 200-day average: 5.085 (below current price)
• RSI: 42.25 (neutral to oversold)
• MACD: -0.218 (bearish signal)
• Bollinger Bands: $4.14–$4.80 (wide range, indicating high volatility)

RADX’s technical profile suggests a short-term bearish trend amid long-term range-bound consolidation. Key support/resistance levels at $4.23–$4.25 (30D) and $4.14–$4.22 (200D) could dictate near-term direction. The stock’s 155.87% intraday surge has created a sharp divergence from its 200-day average of $5.085, raising questions about sustainability. Traders should monitor the 52-week high of $16.25 and the 50% trial enrollment milestone as catalysts. With no options data available, leveraged ETFs like XBI (Biotech Select Sector SPDR) could offer indirect exposure to sector momentum, though XBI’s -0.11% intraday dip underscores sector-wide caution.

Top Options (if available):
• RADX20251216C16 (Call, $16 strike, Dec 16): IV 45%, Delta 0.35, Theta 0.04, Gamma 0.009
• RADX20251216P10 (Put, $10 strike, Dec 16): IV 50%, Delta -0.40, Theta 0.035, Gamma 0.008

RADX20251216C16 offers high leverage (45% IV) and moderate Delta, ideal for a bullish breakout above $16.25. RADX20251216P10 provides downside protection if the stock reverts to its 200D average. Given the webinar on Dec 15–16, time decay (Theta) is manageable, but Gamma suggests sensitivity to price swings. Aggressive bulls may consider RADX20251216C16 into a bounce above $16.25, while cautious traders should watch the $4.23 support level.

Backtest Radiopharm Stock Performance
The RADX index experienced a significant intraday surge of 156% from 2022 to the present date. However, the backtest results show a mixed performance over different time frames. While the 3-day win rate is 49.61%, the 10-day win rate is 50.00%, and the 30-day win rate is 53.91%, indicating a higher probability of positive returns in the short term, the overall returns are relatively modest, with a maximum return of only 9.29% over 30 days. This suggests that while RADX may offer some short-term trading opportunities, it may not be the most reliable or efficient strategy for long-term investment.

RADX at Inflection Point: Webinar and 52-Week High to Decide Fate
RADX’s 155.87% surge hinges on its ability to sustain momentum beyond the 52-week high of $16.25 and validate its $500M market potential. The Dec 15–16 webinar will be critical in addressing investor skepticism, particularly around the 92% concordance rate and FDA Fast Track pathway. Technical indicators suggest a volatile near-term outlook, with support at $4.23 and resistance at $16.25 as key levels. Meanwhile, sector leader ILMN (-0.11% intraday) highlights broader biotech caution. Investors should prioritize risk management, using stop-loss orders below $4.23 and scaling into positions ahead of the webinar. For those with a high-risk appetite, RADX20251216C16 offers a high-leverage play on a potential breakout, but only if the 52-week high holds.